Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 6/20 | 0.41 |
| ▸ | PIK3R1 | P27986 | 5/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4175473 | 0.91 | PIK3CD (0.39) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL4806235 | 0.80 | HTR6 (0.42) | ALDH1A1 | |
| SCHEMBL4808337 | 0.80 | LMNA (0.40) | CNR2SMN1; SMN2TSHR | |
| SCHEMBL4904705 | 0.79 | MET (0.41) | — | |
| SCHEMBL2946889 | 0.79 | FSCN1 (0.42) | — | |
| SCHEMBL4175452 | 0.77 | ALOX5AP (0.37) | — | |
| SCHEMBL4809762 | 0.77 | MOK (0.41) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL4166906 | 0.77 | L3MBTL1 (0.46) | CNR2SMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL2949605 | 0.76 | MET (0.39) | — | |
| SCHEMBL13778782 | 0.76 | KCNH2 (0.46) | PIK3CACNR2SMN1; SMN2TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170846-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC | 2009-07-02 | — | — | US | claimed |
| US-20090170846-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC | 2009-07-02 | — | — | US | disclosed |
| US-20090170846-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC | 2009-07-02 | — | — | US | disclosed |
| US-20090170846-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC | 2009-07-02 | — | — | US | disclosed |
| WO-2007039802-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER PRODUCTS INC. (US) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170846-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | IMPDH1, IMPA1, TYMP | PIK3CA 180/4885PIK3R1 804/4885PIK3CD 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.